Hematoporphyrin-derived soluble porphyrin-platinum conjugates with combined cytotoxic and phototoxic antitumor activity

Journal of Medicinal Chemistry

Volumn 45, Issue 10, 2002, Pages 2064-2078

  Lottner, Christian ^a   Bart, Karl Christian ^a   Bernhardt, Günther ^a   Brunner, Henri ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

7,12 BIS[[1 [POLY(ETHYLENEGLYCOL)MONOMETHYLETHER 1 YL]ETHYL] 3,8,13,17 TETRAMETHYLPORPHYRIN 2,18 DIPROPIONATO]PLATINUM; CISPLATIN DERIVATIVE; CYTOTOXIC AGENT; DIAMINE; HEMATOPORPHYRIN DERIVATIVE; PHOTOSENSITIZING AGENT; PLATINUM DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CHEMOSENSITIVITY; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; IRRADIATION; PHOTOTOXICITY; TRANSITIONAL CELL CARCINOMA;

AGED; ANTINEOPLASTIC AGENTS; CHELATING AGENTS; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HEMATOPORPHYRINS; HUMANS; LIGANDS; LIGHT; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PHOTOSENSITIZING AGENTS; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0037046604     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0110688     Document Type: Article

References (66)

1. Risk of bladder cancer by source and type of tabacco exposure; a case-control study
2. BTA TRAK - A useful diagnostic tool in urinary bladder cancer?
3. Urine cytology, tumor markers and bladder cancer
4. Cancer incidence and mortality in the European Union: Cancer registry data and estimates of national incidence for 1990
5. Gemcitabine and cisplatin in locally advanced and/or metastatic bladder cancer
6. Chemotherapy for advanced bladder cancer
7. NCCN urothelial cancer practice guidelines
8. Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin and cisplatin in patients with unresectable or metastatic transitional cell carcinoma
9. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: The Princess Margaret Hospital experience
10. Usefulness and limitations for methotrexate, vinblastine, doxorubicin and cisplatin for the treatment of advanced urothelial cancer
11. Long-term follow-up in patients treated with methotrexate, vinblastine, doxorubicin and cisplatin (M-VAC) for transitional cell carcinoma of urinary bladder: Cause of concern
12. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced carcinoma of the bladder
13. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A Cooperative Group study
14. A prospective randomized trial comparing M-VAC and CISCA chemotherapy for patients with metastatic urothelial tumors
15. Toxicity and results of MVAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy in advanced urothelial carcinoma
16. BCG immunotherapy for superficial bladder cancer
17. Intravesical therapy for bladder cancer
18. Photodynamic therapy
19. Uptake, localization and photodynamic effect of meso-tetra(hydroxyphenyl)-porphine and its corresponding chlorin in normal and tumor tissues of mice bearing mammary carcinoma
20. How does photodynamic therapy work?
21. Photodynamic therapeutics: Basic principles and clinical applications
22. Effect of photodynamic therapy in combination with mitomycin C on a mitomycin-resistant bladder cancer cell line
23. Antitumor efficacy of the combination of photodynamic therapy and chemotherapy in murine tumors
24. Synthese und Antitumoraktivität neuer porphyrin-platin(II)-komplexe mit an den porphyrin-seitenketten gebundenem cytostatischen platin-rest
25. Platin(II)-komplexe mit porphyrinliganden - Additive cytotoxische und photodynamische wirkung
26. Platin(II)-komplexe mit porphyrinliganden: Synthese und synergismen bei der photodynamischen tumortherapie
27. Synthesis and in vitro testing of hematoporphyrin type ligands in platinum(II) complexes as potent cytostatic and phototoxic antitumor agents
28. Current status of platinum-based antitumor drugs
29. Platinum compounds in cancer therapy
30. Evolution of chemotherapy with platinum compounds
31. Yearly review. Photochemotherapy of cancer: Experimental research
32. Substituted deuterioporphyrins. I. Reactions at the periphery of the porphyrin ring
33. Crystalline synthetic porphyrin c
34. The stereochemistry of complex inorganic compounds. X. The stereoisomers of dichlorobis-(ethylenediamine)-platinum(IV) chloride
35. Antitumor activity of 1,2-diaminocyclohexane-platinum complexes against sarcoma-180 ascites form
36. Researches on residual affinity and coordination. Part XXXIV. 2: 2′-dipyridyl platinum salts
37. Synthesis and characterization of cyclomaltoheptaose-based metal chelants as probes for intestinal permeability
38. Tissue distribution properties of technetium-99m-diamide-dimercaptide complexes and potential use as renal radiopharmaceuticals
39. Rac.-di-2-pyrrolidonyl-(5,5′), ein zwischenprodukt zur synthese von corrinkomplexen
40. Synthesis of substituted 1,5-and 1,7-naphthyridines and related lactams
41. Antitumor activity of Pt(II) complexes containing diaminocarboxylates and their ester derivatives
42. Mechanism of action of tumor-inhibiting metal-complexes
43. A cell line from an anaplastic transitional cell carcinoma of human urinary bladder
44. Human bladder cancer cell lines: HLA class I and class II antigen espression and susceptibility to cytostatic and cytolytic effects in vitro
45. Computerized determination of growth kinetic curves and doubling times from cells in microculture
46. Standardized kinetic microassay to quantitate differential chemosensitivity based on proliferative activity
47. Metallkomplexe in der krebstherapie
48. New approaches to the design of platinum antitumor agents
49. Platinum Compounds
50. Platin-komplexe in der krebstherapie
51. Neue cisplatin-analoga-auf dem weg zu besseren cancerostatica
52. DNA cell growth in chemotherapy of cancer
53. The mechanism of action of platinum antitumor drugs
54. 2]
55. Oxaliplatin: A review of its use in the management of metastatic colorectal cancer
56. Oxaliplatin clinical activity: A review
57. Indocyanine green: Intracellular uptake and phototherapeutic effects in vitro
58. Dose-dependent photodynamic effects of 9-acetoxy-2,7,12,17-tetrakis-(β-methoxyethyl)-porphycene in vitro
59. Indocyanine green (ICG) and laser irradiation induced photooxidation
60. Synthesis and characterization of new polyethyleneoxy substituted salicylaldimine Schiff bases and some corresponding reduced tetra- and pentaaza ligands and their gadolinium(III) complexes: New potential contrast agents in magnetic resonance imaging
61. Nomenclature of tetrapyrroles
62. The seed stock concept and quality control for cell lines
63. Different response of murine and human mammary tumor models to a series of diastereoisomeric [1,2-bis(difluorophenyl)-ethylenediamine]dichloroplatinum(II) complexes